Gemini Therapeutics, Inc.
Gemini Therapeutics, Inc. (GMTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gmtx · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Gemini Therapeutics, Inc.You GMTX | $25M | N/A | — | — |
 Allakos Inc. ALLK | $30M | N/A | — | -$1.30 |
 Angion Biomedica Corp. ANGN | $30M | N/A | — | -$2.58 |
 AnPac Bio-Medical Science Co., Ltd. ANPC | $27M | N/A | — | -$54.18 |
 Elevation Oncology, Inc. ELEV | $22M | N/A | — | -$0.78 |
 Freeline Therapeutics Holdings plc FRLN | $28M | N/A | — | -$22.52 |
 Liminal BioSciences Inc. LMNL | $28M | N/A | — | -$341.80 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Gemini Therapeutics, Inc. (GMTX) measures how much investors pay for each dollar of the company's trailing earnings. GMTX's current PE ratio of N/A is calculated by dividing its stock price of $1.35 by its TTM earnings per share of —.
Frequently asked questions
GMTX pe ratio · 6 questionsGMTX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.35 and TTM EPS of —. Data sourced from Financial Modeling Prep via GMTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Gemini Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09